Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1513525 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $2.95Day +4.98%Mkt cap $6M1Y −81.3%Off 52W high −84.5%Vol (1Y) 88.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,007 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest11.4% of sh out |
| Days to cover5.3d |
| 13F net flow (QoQ)−10.00% |
| Top-10 13F concentration100.0% |
| Next report (est.)2026-08-07 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$7.8M |
| ROE−170.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−46.4% |
| 1Y−81.3% |
| 3Y−98.3% |
| 5Y−99.8% |
| Since incept. (ann.)−57.0% |
Total return through 2026-07-28 · series begins 2018-07-27. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)88.6% |
| Ann. volatility (3Y)142.2% |
| Sharpe (1Y)−1.48 |
| Sharpe (3Y)−0.37 |
| Max drawdown (1Y)−91.4% |
| Max drawdown (3Y)−99.3% |
| Beta (3Y vs SPY)1.66 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 24,249 | $43,405 | 1.13% | −84.4% |
| VANGUARD FIDUCIARY TRUST CO | 5,879 | $10,523 | 0.27% | new |
| Manchester Capital Management LLC | 1,923 | $3,443 | 0.09% | −96.0% |
| Tower Research Capital LLC (TRC) | 1,356 | $2,427 | 0.06% | +1.1% |
| BlackRock, Inc. | 1,110 | $1,987 | 0.05% | −96.0% |
| UBS Group AG | 542 | $970 | 0.03% | −94.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 361 | $646 | 0.02% | new |
| MORGAN STANLEY | 50 | $90 | 0.00% | +455.6% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-08 | −$1.48 | — | — | — |
| 2025-09-30 | 2025-11-13 | — | — | — | — |
| 2025-06-30 | 2025-08-13 | — | — | — | — |
| 2025-03-31 | 2025-05-14 | — | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-07 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
